Transformation Capital has closed its fourth fund at an $850 million hard cap, exceeding its target in an oversubscribed fundraising process as the healthcare-focused investment firm expands its backing of digital health and AI companies.
Fund IV attracted continued commitments from existing limited partners along with a group of new institutional investors. Transformation Capital has already begun deploying capital from the fund into new portfolio companies.
The new vehicle increases Transformation Capital’s assets under management to more than $2.5 billion across four funds.
The firm invests exclusively in commercial-stage healthcare technology companies focused on improving the delivery, cost and quality of healthcare.
Transformation Capital sees artificial intelligence as the latest major technology shift reshaping U.S. healthcare following electronic medical record adoption, value-based care and the acceleration of telehealth.
The firm said it has made eight new AI-focused investments during the past year alone.
Fund IV will continue targeting companies applying technology and AI to improve healthcare efficiency, accessibility and accountability, including businesses addressing what Transformation Capital describes as more than $1 trillion of waste and inefficiency within the U.S. healthcare system.
The firm sees a particularly large opportunity around the healthcare industry’s enormous but underutilized data base. Transformation Capital said healthcare generates roughly 30% of the world’s data while meaningfully using only about 3% of it.
Transformation Capital has invested in more than 50 digital health and AI-driven healthcare companies. Portfolio companies include Datavant, Judi Health, Sword Health, Grow Therapy, SmarterDx and Parachute Health.
Beyond providing capital, the firm emphasizes strategic introductions to health plans, hospital systems, self-insured employers and biopharmaceutical companies as well as executive recruiting and operational support.
Transformation Capital is led by Managing Partners Todd Cozzens, Jared Kesselheim and Mike Dixon.
Cozzens previously founded and led Marquette Medical, which went public before being acquired by GE, and Picis, which was acquired by UnitedHealth Group. He later invested in healthcare technology at Sequoia.
Kesselheim is a physician who practiced internal medicine at Massachusetts General Hospital before becoming a healthcare investor at Bain Capital Ventures.
Dixon previously worked at Fidelity Investments and spent a decade as a General Partner at Sequoia focused on healthcare investing.
The $850 million close gives the firm additional capital at a time when healthcare organizations are rapidly evaluating how AI can automate administrative processes, improve clinical workflows and extract more value from existing healthcare data.
KEY QUOTES:
“The demand we saw for Fund IV is a strong endorsement of our strategy at a pivotal moment for innovation in our U.S. healthcare system.”
“We are very pleased to have continued support from many of our existing partners, and we are equally energized by the caliber of new institutional investors who joined us for the first time.”
Jessica Pellegrini, Head of Capital Formation at Transformation Capital
“We started this firm because we’d been the entrepreneurs, the clinicians, and the longtime focused investors in this industry, and we know exactly where technology can make the biggest difference: improving outcomes, lowering costs, and improving the patient experience.”
“Artificial intelligence is having its biggest impact yet. It is the single largest market driver we have seen in the nearly two decades we have been investing in this space.”
Todd Cozzens, Jared Kesselheim and Mike Dixon, Managing Partners of Transformation Capital
